Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Liquid Biopsy: Level of mutated DNA in the blood corresponds to patient outcome

No. 39 | 20/09/2016 | by HC/Sel

New findings from a scientific collaboration between the German Cancer Research Center (DKFZ), the National Center for Tumor Diseases (NCT) Heidelberg and the Thoraxklinik Heidelberg suggest liquid biopsy as a promising tool to monitor lung cancer patient tumors early. Scientists associated liquid biopsy readouts with clinical data and were able to track tumor responses to cancer drugs in real-time. Their paper has just been published in the latest issue of Scientific Reports.

© Photograph by Graham Beards, distributed under a CC BY-SA 3.0 and present on Wikimedia Commons.

Effective treatment of cancer relies on the diagnosis of the patient’s sample. Commonly, tissue biopsies are performed and mutations observed in these samples can inform physicians of the appropriate therapy to be prescribed.

Although currently considered the ‘gold standard’, tissue biopsies are not without limitations. The realization that molecular abnormalities and mutations in tumors dynamically change in regards to time and treatment has raised questions on whether tissue biopsies are sensitive enough to capture such changes. Furthermore, as Professor Holger Sültmann, the head of the Cancer Genome Research Group of the DKFZ explains, ‘tissue biopsy is much more invasive, and in some cases a risky procedure.’

In recent years a new alternative, termed liquid biopsy, is gaining attention. When cells die, they release their DNA (so-called cell free DNA, cfDNA) into the bloodstream. For tumor cells that die after therapy, the cfDNA contains mutations that could be detected and analyzed with PCR or sequencing tools for non-invasive diagnosis. ‘In contrast (to tissue biopsy), liquid biopsy is simply drawing a few milliliters of blood, isolating the DNA and performing the molecular analysis,’ commented Professor Sültmann on the method’s advantage.

However, the sensitivity and clinical information provided by liquid biopsy is less clear. This prompted the group to investigate further. By collaborating with partners at the Heidelberg Thoraxklinik, the DKFZ researchers recruited a focused cohort of 16 lung cancer patients, all of whom carried prominent mutations, and were undergoing tyrosine kinase inhibitor (TKI) treatment. Over a period of up to two years, the researchers collected sequential blood plasma samples from each patient and extracted the DNA. Using digital PCR assays, they looked for cfDNAs containing mutations, and compared the number of detected mutations with clinical data at all possible timepoints.

‘Initially we didn’t know what to expect. We wanted to test if it is possible at all to identify mutational changes in the (blood) plasma over time, and whether we can associate these with clinical parameters.’ By analyzing the data, the scientists made three interesting observations.

First, the number of mutated alleles in patients changed in accordance to the clinical course of the disease. For example, in one patient, the initiation of TKI therapy was paralleled by a drastic and immediate (within 26 hours) rise of mutated cfDNA in the blood plasma, probably indicative of an effective therapy response that resulted in many cancer cell deaths. Interestingly, this ‘peak’ declined shortly afterwards, suggesting that TKI therapy had its greatest impact only during the first few days of treatment. ‘’This indicates that we have to monitor very closely around the timepoint of TKI therapy onset,’’ Professor Sültmann remarked.

Secondly, the researchers also found that low, or absent levels of mutated cfDNA associated with sustained periods where the disease remained under control and the tumor did not grow. Finally, in patients whose tumor relapsed and who died soon afterwards, the mutated cfDNA levels were found to be increasing rapidly over short timeframes. In some cases, this increase was observable even before the actual clinical manifestation.

These findings highlight liquid biopsy’s sensitivity in detecting and reflecting tumor changes in real time, while providing the advantages of being less invasive. The molecular data provided by this method might also help inform physicians to make earlier decisions on therapeutic strategies. Nonetheless, due to the study’s preliminary nature, Professor Sültmann reminds that a lot more work remains be done: ‘’This is a ‘proof of concept’, we should really collect and measure cfDNA more systematically in order to learn what the liquid biopsy can do under these circumstances, and to fully comprehend the principles of lung cancer progression.’’

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients.

Riediger AL, Dietz S, Schirmer U, Meister M, Heinzmann-Groth I, Schneider M, Muley T, Thomas M, Sültmann H. Sci Rep. 2016 Sep 19;6:33505. doi: 10.1038/srep33505.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS